<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186185</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006240</org_study_id>
    <nct_id>NCT01186185</nct_id>
  </id_info>
  <brief_title>Fludrocortisone for Sudden Hearing Loss</brief_title>
  <official_title>Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard of care treatment of sudden hearing loss uses a type of steroid called&#xD;
      glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and&#xD;
      dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone&#xD;
      is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work&#xD;
      by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In&#xD;
      animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving&#xD;
      hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The&#xD;
      purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI moved to new institution, unable to complete study&#xD;
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing</measure>
    <time_frame>At one month</time_frame>
    <description>Hearing outcome will be determine by pure-tone and speech audiometry measured at the completion of a one-month course of treatment and compared with pre-treatment test results.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hearing Loss, Sensorineural</condition>
  <arm_group>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>Fludrocortisone 0.2 mg by mouth daily for 30 days</description>
    <arm_group_label>Fludrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Idiopathic sudden sensorineural hearing loss within 3 months&#xD;
&#xD;
          -  Failure to recover hearing with glucocorticoid treatment or inability to tolerate&#xD;
             glucocorticoid&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other diagnosis for the sudden hearing loss&#xD;
&#xD;
          -  Concurrent systemic use of another steroid&#xD;
&#xD;
          -  Hypersensitivity to fludrocortisone&#xD;
&#xD;
          -  Systemic fungal infection&#xD;
&#xD;
          -  Hypertension requiring two or more medications&#xD;
&#xD;
          -  Pitting edema&#xD;
&#xD;
          -  Cardiomegaly&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Electrolyte abnormality&#xD;
&#xD;
          -  Concurrent use of barbiturates, phenytoin, fosphenytoin, rifampin, or rifapentine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anh Nguyen-Huynh, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sudden</keyword>
  <keyword>sensorineural</keyword>
  <keyword>hearing loss</keyword>
  <keyword>fludrocortisone</keyword>
  <keyword>mineralocorticoid</keyword>
  <keyword>steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

